Background: The outcome of approximately 20% of patients with acute lymphoblastic leukemia (ALL) remains poor because of disease recurrence. We examined whether DNA methylation of cadherin superfamily genes is a useful biomarker for ALL relapse. 
INTRODUCTION
The cure rate of childhood acute lymphoblastic leukemia (ALL) has improved over the past four decades. However, the prognosis of approximately 20% of patients with ALL remains poor because of disease recurrence. A main cause of refractory ALL is the development of chemotherapeutic drug-resistant clone(s). [1] [2] [3] The acquisition of chemoresistance is considered to be associated with either genetic or epigenetic alterations. [4] [5] [6] Moreover, recent studies demonstrated Abbreviations: ALL, acute lymphoblastic leukemia; BCP, B-cell precursor; BM, bone marrow; COBRA, combined bisulfite restriction analysis; CR, complete remission; DAVID, Database for Annotation, Visualization, and Integrated Discovery; EFS, event-free survival; HR, hazard ratio; MNCs, mononuclear cells; MLPA, multiplex ligation-dependent probe amplification; OS, overall survival; PB, peripheral blood; RT-PCR, reverse-transcriptase PCR; WBC, white blood cell that relapse clones are already present as a small subset of leukemic cells at the diagnosis and eventually reemerge as the major clone at relapse. 7 In recent years, many studies have attempted to identify new clinical biomarkers that can predict high-risk patients, and thus serve as targets for novel therapeutic interventions, using geneexpression microarrays, DNA-methylation arrays, and next-generation sequencing. [8] [9] [10] [11] DNA methylation and histone modifications are the two major epigenetic mechanisms regulating gene expression. Hypermethylation of CpG islands in the promoter region of tumor suppressor genes, which results in transcriptional silencing, plays an important role in lymphoidlineage leukemogenesis and may be an important contributor toward relapse. 4, 5 Moreover, DNA methylation profiling is useful for the subtype classification of newly diagnosed patients with ALL and prediction of outcome and relapse risk. 12 Here we present data demonstrating that methylation of protocadherin (PCDH) 17, a member of nonclustered protocadherins, is related to a poor prognosis and thus propose PCDH17 methylation as a novel biomarker to predict a relapse in patients with B-cell precursor (BCP) ALL. 
MATERIALS AND METHODS

Clinical samples and leukemic cell lines
Infinium Methylation 450K Array
To examine the methylation status of the BM samples at diagnosis, CR, and relapse in a relapsed patient with BCP ALL, global DNA methy- 
Combined bisulfite restriction analysis and bisulfite sequencing
Genomic DNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen, Chuo-ku, Tokyo, Japan), followed by sodium bisulfite treatment using the EZ DNA Methylation Kit (Zymo Research, Irvine, CA, USA) as reported previously. 13, 14 PCR reaction was performed as described previously. 15 For combined bisulfite restriction analysis (COBRA), PCR products were digested with BstUI enzyme (New England BioLabs Japan Inc., Tokyo, Japan) and electrophoresed on agarose gels stained with ethidium bromide. The minimal amount of methylated DNA detectable in an unmethylated DNA pool was 20%.
For bisulfite sequencing of the PCDH17 CpG island, 10 l of each PCR product was electrophoresed onto a 3% agarose gel. The bands were then excised and purified using the Geneclean 2 Kit (Bio 101 Inc., La Jolla, California). Purified PCR products were cloned into the pGEM-T Easy vector (Promega Corp., Madison, Wisconsin). The plasmids were extracted using the Wizard Plus Minipreps DNA Purification System (Promega). Individual clones were sequenced on the ABI PRISM 3100
Genetic Analyzer (Applied Biosystems) using the DYEnamic ET Terminator Cycle Sequencing Kit (Amersham Biosciences, Piscataway, New Jersey).
Reverse-transcriptase PCR and quantitative real-time PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and cDNA was prepared using PrimeScript II first strand cDNA Synthesis Kit (Takara Bio Inc.). The cDNA was used as a template for reversetranscriptase PCR (RT-PCR) and quantitative real-time PCR with primers and probes listed in Supplementary Table S2 . RT-PCR was performed as reported previously. 15 Real-time PCR was carried out in an ABI sequence detection system using the Master Mix (Applied Biosystems). Each assay was performed in triplicates for each sample. 
Multiplex ligation-dependent probe amplification
Statistical analyses
The chi-square or Fisher exact test was used to determine the association of the methylation of PCDH17 with that of other cadherin superfamily genes and to compare their methylation status at diagnosis with that at relapse. Spearman rank correlation test was performed to determine the relationship between two variables.
Actuarial estimates of event-free survival (EFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Patients were censored for EFS if they were alive and in remission at the last follow-up and censored for OS if they were alive at the last followup. Follow-up data were available through December 31, 2014. Risk factors for relapse or mortality were applied to the univariate and multivariate Cox proportional hazards regression analysis. All P values were two-sided, and P values of 0.05 or less were considered statistically significant. All statistical analyses were performed with 
RESULTS
Methylation status of cadherin superfamily genes in BCP ALL
The genome-wide DNA methylation status of BM samples (at diagnosis, CR, and relapse) of a 2-year-old male diagnosed with BCP ALL was examined, followed by the functional analysis of large gene lists using the bioinformatics DAVID program, which identified cadherin superfamily genes as the top candidate genes with aberrant methylation at relapse (Supplementary Appendix S1). Among these cadherin superfamily genes, Cadherin (CDH) 1, PCDH8, and PCDH17 were previously demonstrated as tumor suppressor genes and frequently detected as hypermethylated in various cancers such as gastric, esophageal squamous cell, hepatocellular, and breast cancers. [16] [17] [18] [19] Therefore, we selected these three genes for further analysis. First, we examined the methylation status of CDH1, PCDH8, and PCDH17 in six ALL cell lines, in 40 newly diagnosed Ph1-negative patient samples with BCP ALL and in control PB and BM cells using the COBRA method. The results are shown in Fig 1. CDH1 and PCDH8 methylation was observed in all cell lines, whereas PCDH17 methylation was detected in four.
CDH1, PCDH8
, and PCDH17 were methylated in 62.5, 55, and 30% of samples from patients with ALL, respectively. However, methylation of PCDH8 and CDH1 was also detected in 80 and 20% of the control BM samples, respectively. These findings were partly due to methylation in CD71-positive BM cells. In contrast, PCDH17 was unmethylated in the control BM cells. There was a significant association between CDH1 methylation and PCDH8 methylation (P < 0.001). Furthermore, PCDH17 methylation was associated with methylation of both CDH1
and PCDH8 (P = 0.018 and P = 0.013, respectively).
Thereafter, we compared the methylation status of 31 PCDH17
CpG sites at diagnosis and at relapse in three patients using bisulfite sequencing. As presented in Supplementary Figure S2 , the total number of methylated PCDH17 sites obtained from eight clones increased significantly at relapse as compared with those obtained from clones at diagnosis in two of three patients (P < 0.0001).
We examined the relationship between methylation status and mRNA expression of PCDH17 in various cell types. PCDH17 methylation was almost negligible in control PB cells, whereas the total number of methylated sites varied among patient samples with ALL and ALL cell lines, as determined by bisulfite sequencing (Supplementary Fig.   S3 ). The control PB cells expressed PCDH17 mRNA due to the presence of PB CD33 + cells, whereas mRNA was variable in patient samples with ALL and ALL cell lines (Supplementary Fig. S4 ). There was no correlation between PCDH17 methylation and mRNA expression levels ( Supplementary Fig. S5 ). 4] ), although the ALL protocols were different between the two groups. Thus, we analyzed the impact of methylation of cadherin superfamily genes on the outcomes of all 40 patients. EFS of the PCDH17 methylation-positive group was profoundly inferior to that of the PCDH17 methylation-negative group: 33% (95% CI: 10-59) versus 75% (95% CI: 55-87) (P = 0.005; Fig 2) . A significant difference in OS was also found between the two groups: 50% (95% CI: 21-73) versus 82% (95% CI: 62-92) (P = 0.016). Conversely, there were no substantial correlations between the methylation status of CDH1 and EFS or OS and between the methylation status of PCDH8 and EFS or OS.
TA B L E 1 Relationship between the methylation status of cadherin superfamily genes at diagnosis and clinical characteristics of patients with BCP ALL
CDH1
As shown in Table 2 , univariate analysis revealed that PCDH17 methylation was associated with an increased risk for relapse and mor- 
DISSCUSSION
DNA hypermethylation plays a significant role in leukemogenesis and hematologic relapse in ALL. 4, 5 For a comprehensive evaluation of the DNA methylation in a pediatric patient with ALL, we performed a genome-wide DNA methylation analysis. The patient already harbored the relapse clone as a minor population at diagnosis. Therefore, to identify the candidate genes associated with relapse, we selected genes that were methylated at higher levels at relapse than at onset.
As a result, cadherin superfamily genes, including CDH1, PCDH8, and PCDH17, were the top gene family in this patient. Among 40 samples from patients with ALL at diagnosis, the methylation frequencies of CDH1, PCDH8, and PCDH17 were 62.5, 55, and 30%, respectively.
The methylation of CDH1 and PCDH8 was also detected in 80 and 20% of the control BM samples, respectively. On the contrary, PCDH17
was unmethylated in all 10 control BM samples. These results suggest that PCDH17 methylation is a specific phenomenon for ALL blasts at diagnosis. PCDH17 is a member of nonclustered protocadherin, a subfamily of cadherin superfamily genes. 23 PCDH17 is frequently downregulated through promoter hypermethylation in a number of cancers. [24] [25] [26] The restoration of PCDH17 expression reduces cell proliferation and migration in esophageal squamous cell carcinoma 17 and induces tumor cell apoptosis and autophagy in gastric and colorectal cancers. 18 However, there was no correlation between methylation status and mRNA expression level of PCDH17 in patients with BCP ALL in this study, implying the involvement of alternative mechanisms in the regulation of PCDH17 gene expression. Accordingly, the association of PCDH17 methylation with a poor prognosis may occur through a mechanism that is independent of methylation-mediated transcriptional silencing.
In our genome-wide DNA methylation analysis of one relapsed patient with BCP ALL, the relapse-mediated increases in the beta values of PCDH10, CDH11, and CDH13 methylation were less than 0.3.
Therefore, we excluded these three genes from subsequent candidate gene analyses in this study. However, Narayan et al. 27 identified PCDH10 hypermethylation in approximately 80% of patients with B-ALL. Hogan et al. 5 found that CDH1, CDH11, and CDH13 were hypermethylated and downregulated in pediatric patients with relapsed ALL. Considering one single sample patient with a clonal expansion of a minor clone at relapse, we cannot completely rule out the impact of methylation of cadherin superfamily genes other than PCDH17 and other family genes on ALL relapse. 
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